Corbus Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares January 30, 2019
Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis January 3, 2019
Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum December 18, 2018
Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update November 8, 2018
Corbus Pharmaceuticals to Announce Third Quarter 2018 Operational and Financial Results on November 8, 2018 November 5, 2018
Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies October 22, 2018
